← board
RGEN
distress 0/10 · well-funded / low risk$142.39+2%today-17% from 52w high
Revenue
pre-revenue
Liquidity
$785M
Runway
—
Shares 1y
+0%
Price & events
-15.2% over 6M
CatalystRating changeDilutionFinancingdashed = today
+1.6%
1D
-4.1%
1W
+12.7%
1M
+24.8%
3M
-12.3%
6M
+21.6%
1Y
+7.3%
2Y
-32.2%
5Y
-25.3%
All
Overview
- Market Cap
- $8.03B
- Enterprise Value
- $8.00B
- Volume
- 196.21K
- 52 Week Range
- $103 – $172
- Total Shares
- 56.41M
- Float Shares
- 53.36M
- Short %
- 10.76%
- % Held by Insiders
- 5.25%
- % Held by Institutions
- 120.66%
- RVOL
- 0.18x
- Beta
- 1.06
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 1
- 2026-07-28Estimated 45%earningsEarningsEarnings releaseyahoo
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $178 (+25% upside) · 20 analysts
- 2026-07-07BenchmarkHold → Buy
- 2026-07-06Evercore ISI GroupOutperform
- 2026-06-03HSBCBuy
- 2026-05-06JP MorganOverweight
- 2026-05-06BarclaysOverweight
- 2026-04-20Canaccord GenuityHold
Competitors
- none identified
Recent news
- 2026-07-22Repligen to Acquire Bothell's BioLife Solutions in $1.5B Deal - 425business.com
- 2026-07-22Repligen to buy BioLife in $1.5 billion deal to expand cell therapy business - ETPharma.com
- 2026-07-22Repligen targets cell therapy expansion as Waltham firm inks $1.5 billion acquisition - The Business Journals
- 2026-07-22Repligen beefs up cell therapy business with $1.5 billion deal for BioLife - Reuters
- 2026-07-22What's Going on With Repligen Stock Wednesday? - Repligen (NASDAQ:RGEN), BioLife Solutions (NASDAQ:BLFS) - Benzinga
- 2026-07-22Repligen Corporation (Nasdaq: RGEN) sets cash–stock deal to buy BioLife - Stock Titan
- 2026-07-22Repligen to Acquire BioLife Solutions in Cash-and-Stock Deal; $11.25 Plus 0.1442 Shares Per Share - TradingView
- 2026-07-22Repligen to Acquire BioLife Solutions in $1.5 Billion Deal - sekbernews.id
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.